CT volume measurement for liver cancer treatment planning
Part of Cancer, Digestive system clinical trials.
This trial uses CT scans to measure the volume of liver tumors in people with hepatocellular carcinoma (HCC) who cannot have surgery. The goal is to see if this measurement helps guide treatment with TACE, a procedure that blocks blood flow to the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with liver cancer (HCC) using standard guidelines
- Your tumor cannot be surgically removed, as decided by a team of specialists
- You are scheduled to have TACE as your main liver-directed treatment
- Your liver function is good enough (Child-Pugh class A or B) and your kidneys can handle the CT contrast dye
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special type of CT scan (spectral CT) to see how well liver cancer has responded to a previous TACE treatment. If you've already had TACE for your liver cancer, this scan may help your doctors decide on the next steps, such as surgery or another procedure.
This study looks at special blood markers in people with liver cancer (hepatocellular carcinoma) who are about to have a procedure called TACE. The goal is to see if these markers can help predict how well the treatment works. You may be able to join if you are getting TACE as part of your standard care.
This study is looking for blood markers that may help doctors learn how well TACE treatment is working for liver cancer. You need to be scheduled for TACE and have a follow-up scan to participate.
This trial is testing a new computer tool that uses your own scans to plan TARE treatment for liver cancer. The goal is to make the treatment more personalized and effective.
This trial combines a targeted drug and immunotherapy with procedures that deliver cancer-killing beads or chemotherapy directly to your liver tumor. It is designed for people with large, inoperable liver cancer that has spread into the main vein leading to the heart.
This trial tests whether adding nitroglycerin (a blood vessel-opening medication) during a standard liver cancer treatment called TACE can improve blood flow to the tumor and help imaging see changes better. It is for people with a single, untreated liver tumor who are generally in good health.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.